Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 1-8 , February 2010

Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis

  • Wassana Yantasee, PhD

      Affiliations

    • Oregon Health and Science University, Portland, Oregon, USA
    • Corresponding Author InformationCorresponding author. Pacific Northwest National Laboratory (PNNL), Richland, WA 99352, USA.
    • ,
  • Glen E. Fryxell, PhD

      Affiliations

    • Pacific Northwest National Laboratory (PNNL), Richland, Washington, USA
    • ,
  • George A. Porter, MD

      Affiliations

    • Oregon Health and Science University, Portland, Oregon, USA
    • ,
  • Kanda Pattamakomsan, MS

      Affiliations

    • Pacific Northwest National Laboratory (PNNL), Richland, Washington, USA
    • ,
  • Vichaya Sukwarotwat, BS

      Affiliations

    • Pacific Northwest National Laboratory (PNNL), Richland, Washington, USA
    • ,
  • Wilaiwan Chouyyok, PhD

      Affiliations

    • Pacific Northwest National Laboratory (PNNL), Richland, Washington, USA
    • ,
  • View Koonsiripaiboon, BS

      Affiliations

    • Pacific Northwest National Laboratory (PNNL), Richland, Washington, USA
    • ,
  • Jide Xu, PhD

      Affiliations

    • University of California, Berkeley, California, USA
    • ,
  • Kenneth N. Raymond, PhD

      Affiliations

    • University of California, Berkeley, California, USA

Received 19 November 2008 ,Accepted 4 May 2009.

References 

  1. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  2. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174–3178
  3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001
  4. Galan A, Cowper S, Bucala ER. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;18:614–617
  5. U.S. Food and Drug Administration . FDA requests boxed warning for contrast agents used to improve MRI images. Silver Spring, MD: U.S. FDA; 2007;
  6. IMV . 2007 MRI market summary report. Greenbelt, MD: IMV; 2008;
  7. Othersen JB, Maize-Jr JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179–3185
  8. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502
  9. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339–341
  10. Tombach B, Bremer C, Reimer P, Matzkies F, Schaefer RM, Ebert W, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. American J Roent. 2002;178:105–109
  11. Penfield JG, Reilly RF. What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol. 2007;3:654–668
  12. Prince MR, Zhang HL, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2003;248:807–816
  13. Fryxell GE, Lin Y, Fiskum S, Birnbaum JC, Wu H, Kemner K, et al. Actinide sequestration using self-assembled monolayers on mesoporous supports. Environ Sci Technol. 2005;39:1324–1331
  14. Fryxell GE, Wu H, Lin Y, Shaw WJ, Birnbaum JC, Linehan JC, et al. Lanthanide selective sorbents: self-assembled monolayers on mesoporous supports (SAMMS). J Chem Mater. 2004;14:3356–3363
  15. Lin Y, Fiskum SK, Yantasee W, Wu H, Mattigod SV, Vorpagel E, et al. Incorperation of hydroxypyridinone ligands into self-assembled monolayers on mesoporous supports for selective actinide sequestration. Envi Sci Technol. 2005;39:1332–1337
  16. Yantasee W, Fryxell GE, Lin Y, Wu H, Raymond KN, Xu J. Hydroxypyridinone functionalized self-assembled monolayers on nanoporous silica for sequestering lanthanide cations. J Nanosci Nanotech. 2005;5:527–529
  17. Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant. 2006;21:651–659
  18. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27–30
  19. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26
  20. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol. 2007;80:73–76
  21. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;7:130–137
  22. Medicines and Healthcare products Regulatory Agency (MHRA) . Public assessment report: increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. MHRA; 2007;
  23. Tweed SO, Weaver TR, Cartwright I, Schaefer B. Behavior of rare earth elements in groundwater during flow and mixing in fractured rock aquifers: an example from the Dandenong Ranges, Southeast Australia. Chem Geol. 2006;234:291–307
  24. Gorden AEV, Xu J, Raymond KN, Durbin P. Rational design of sequestering agents for plutonium and other actinides. Chem Rev. 2003;103:4207–4282
  25. Yantasee W, Lin Y, Fryxell GE, Busche BJ, Birnbaum JC. Removal of heavy metals from aqueous solution using novel nanoengineered sorbents: self-assembled carbamoylphosphonic acids on mesoporous silica. Sep Sci Technol. 2003;38:3809–3825
  26. Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med. 2006;24:445–451
  27. Kokot F, Pietrek J, Seredyski M. Influence of hemoperfusion on the concentration of methyldigoxin and hormones in plasma. Kidney Int. 1979;15:404–410
  28. Stamatialis DF, Papenburg BJ, Gironés M, Saiful S, Bettahalli SNM, Schmitmeier S, et al. Medical applications of membranes: drug delivery, artificial organs and tissue engineering. J Membrane Sci. 2008;308:1–34

 This work was partially supported by the Laboratory Directed Research and Development (LDRD) program at PNNL, National Institute of Environmental Health Sciences (NIEHS) grant no. R21 ES015620, and National Institute of Allergy and Infectious Disease (NIAID) grant no. R01 AI074064. A portion of research was performed using EMSL, a national scientific user facility sponsored by the Department of Energy's Office of Biological and Environmental Research and located at PNNL.

PII: S1549-9634(09)00093-8

doi: 10.1016/j.nano.2009.05.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 1 , Pages 1-8 , February 2010

Article Tools

* Image Usage & Resolution